<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02979288</url>
  </required_header>
  <id_info>
    <org_study_id>MUV 012017</org_study_id>
    <nct_id>NCT02979288</nct_id>
  </id_info>
  <brief_title>Treatment of the Intermediate Vaginal Microbiota With Vaginal Lactobacillus Casei Rhamnosus to Improve Pregnancy Outcome</brief_title>
  <acronym>LCR35&amp;PTD</acronym>
  <official_title>Treatment of the Intermediate Vaginal Microbiota With Vaginal Probiotics Containing Lactobacillus Casei Rhamnosus (Lcr Regenerans) to Improve Pregnancy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the currently presented trial, investigators aim to evaluate the treatment of the&#xD;
      intermediate vaginal microbiota during the first trimester of pregnancy with vaginal&#xD;
      lactobacilli to restore the normal vaginal microbiota and therewith reduce the rate of PTD.&#xD;
      All pregnant women between 10 + 0 (10 weeks plus 0 days) and 16 + 0 (16 weeks plus 0 days)&#xD;
      gestational weeks in study group will be treated with vaginal Lactobacilli Capsules&#xD;
      containing L. Casei rhamnosus LCR 35&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite recent achievements in perinatal care, the prevention of preterm delivery (PTD)&#xD;
      remains a major challenge in modern obstetrics. Healthy vaginal flora, dominated by&#xD;
      Lactobacillus species (spp.), plays an important role in the protection against genital&#xD;
      infections, which are considered a frequent cause of PTD. Imbalances of the vaginal flora&#xD;
      caused by a reduction in the proportion of Lactobacillus spp. can lead to an overgrowth of&#xD;
      mixed anaerobic bacteria, which can ultimately result in bacterial vaginosis (BV). Since the&#xD;
      effect of treating pregnant women with an abnormal vaginal flora was introduced, BV has&#xD;
      gained interest and is now a well-known risk factor for ascending infections and subsequent&#xD;
      PTD. However, the overall risk reduction of PTD through antibiotic treatment of an abnormal&#xD;
      flora was disproved by large and well-designed studies in a general obstetrical population.&#xD;
&#xD;
      At present, little is known about the role of the intermediate vaginal flora, which can&#xD;
      either be regarded as the transition from a healthy to an abnormal flora or as the transition&#xD;
      from abnormal flora back to a healthy vaginal microbiota. The intermediate vaginal flora&#xD;
      constitutes a highly heterogeneous group that may or may not include vaginal Lactobacillus&#xD;
      spp. and that may or may not be characterised by the presence of anaerobic bacteria. In 2007,&#xD;
      a meta-analysis reported that the presence of intermediate vaginal flora was not associated&#xD;
      with PTD, late miscarriage, maternal or neonatal infection, or perinatal mortality. In&#xD;
      contrast, an observational study by Hay et al.reported a high rate of late miscarriage (16-24&#xD;
      gestational weeks) in women with intermediate vaginal flora at an examination before 16&#xD;
      gestational weeks. Additionally, another study reported an association of PTD with partial&#xD;
      BV, which is defined as streaks of BV flora in a smear that has areas of normal flora.&#xD;
&#xD;
      Latest research reported that there is an association between the intermediate vaginal flora&#xD;
      and PTD. In one of our previous studies, intermediate flora was identified on the examined&#xD;
      screening smears of 529/8421 (6.3%) women. In this group, 349/529 (66%) women had a Nugent&#xD;
      score of 4, 94/529 (17.8%) had a Nugent score of 5, and 86/529 (16.2%) had a Nugent score of&#xD;
      6. In women with a Nugent score of 4, 232/349 (66.5%) women were assigned to the Lactobacilli&#xD;
      group. The Non-Lactobacilli group consisted of 117/349 (33.5%) women with a Nugent score of 4&#xD;
      due to the total absence of any bacterial colonisation, including Lactobacillus spp. The&#xD;
      preterm delivery rate was significantly lower in the Lactobacilli than in the&#xD;
      Non-Lactobacilli group On follow-up smears, bacterial vaginosis rates were 9% in the&#xD;
      Lactobacilli and 7.8% in the Non-Lactobacilli group. Hence, according to this retrospective&#xD;
      study, the absence of vaginal Lactobacillus species and any bacterial colonisation increases&#xD;
      the risks of preterm delivery and low birth weight in women with intermediate vaginal flora&#xD;
      in early pregnancy.&#xD;
&#xD;
      In the currently presented trial, investigators aim to evaluate the treatment of the&#xD;
      intermediate vaginal flora during the first trimester of pregnancy with vaginal lactobacilli&#xD;
      to restore the normal vaginal microbiota and therewith reduce the rate of PTD.&#xD;
&#xD;
      At investigators Department, pregnancy care includes a prenatal consultation, where women&#xD;
      registered for a planned delivery at our department between 10 + 0 (10 weeks plus 0 days) and&#xD;
      16 + 0 (16 weeks plus 0 days) gestational weeks. Women underwent routine screening for&#xD;
      asymptomatic vaginal infections and characterization due to Nugent score. All women except&#xD;
      those with a normal flora (Nugent score 0 to 3) will be asked to undergo a follow-up smear&#xD;
      between 14 + 0 (14 weeks plus 0 days) and 22 + 0 (22 weeks plus 0 days) gestational weeks at&#xD;
      our department. Vaginal smears will be obtained after vaginal fluid collection with sterile&#xD;
      swabs from the lateral vaginal wall and posterior fornix vaginae. Both at first and control&#xD;
      smear. All smears will be Gram-stained and microscopically analyzed by one of four biomedical&#xD;
      laboratory assistants, specialized in gynecological cytopathology, at a laboratory that is&#xD;
      certified according to DIN EN ISO 9001:2008. Nugent scores of 0 to 3 will be considered to&#xD;
      indicate normal vaginal flora, 4 to 6 to indicate intermediate vaginal flora, and 7 to 10 to&#xD;
      indicate BV.&#xD;
&#xD;
      The present study follows a prospective randomized observer-blinded mono-centric design.&#xD;
      After obtaining the results of vaginal swab According to the Nugent scoring system, two&#xD;
      groups will be assigned: (i) pregnant women with an intermediate vaginal flora and a Nugent&#xD;
      score of 4 with vaginal lactobacilli (Control Group), versus (ii) pregnant women with an&#xD;
      intermediate vaginal flora and a Nugent score of 4 without vaginal lactobacilli (Study&#xD;
      Group).&#xD;
&#xD;
      Therapy will be assigned due to protocol. Each group will be divided in a study and control&#xD;
      group. Patients of the study group will be treated with muco-adhesive slow release vaginal&#xD;
      tablets containing 876,9 mg Lactobacillus casei rhamnosus (Lcr regenerans) in concentration&#xD;
      of 107 CFU/ml (Groups A + C). The treatment duration will be 8 days with two tablets every&#xD;
      4th day. Patients of the control group will not undergo any treatment (Groups B + D). A&#xD;
      vaginal control smear will be obtained 4-6 weeks following the first study visit.&#xD;
&#xD;
      The primary outcome parameter will be the recovery to the normal vaginal flora (Nugent score&#xD;
      0 to 3). Secondary outcome parameters will include (i) the gestational age at delivery,&#xD;
      recorded as term delivery at or after 37 + 0 gestational weeks, (ii) the rate of PTD, defined&#xD;
      as spontaneous delivery at or before 36 + 6 gestational weeks, due to preterm premature&#xD;
      rupture of the membranes and/or preterm labor, (iii) neonatal birthweight, defined as a the&#xD;
      weight at the time of delivery, and (iv) the rate of live birth, defined as the delivery or&#xD;
      PTD of an infant that had an Apgar score at 1 minute of &gt; 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the recovery to the normal vaginal microbiota (Nugent score 0 to 3).</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the gestational age at delivery, recorded as term delivery at or after 37 + 0 gestational weeks</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Lactobacillus Infection</condition>
  <arm_group>
    <arm_group_label>A Nugent 4 + Lactobacilli</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Nugent 4 + Lactobacilli</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Nugent 4 NO Lactobacilli</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D Nugent 4 NO Lactobacilli</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus casei rhamnosus (Lcr 35 regenerans)</intervention_name>
    <description>Probiotic vaginal tablets vith active probiotic strains</description>
    <arm_group_label>A Nugent 4 + Lactobacilli</arm_group_label>
    <arm_group_label>C Nugent 4 NO Lactobacilli</arm_group_label>
    <other_name>Gynophilus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO Intervention</intervention_name>
    <description>NO Intervention</description>
    <arm_group_label>B Nugent 4 + Lactobacilli</arm_group_label>
    <arm_group_label>D Nugent 4 NO Lactobacilli</arm_group_label>
    <other_name>NO Medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women 10th to 16th Week of gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vaginal Bleeding, Twins, vaginal infections, Antibiotics up to 4 weeks to&#xD;
             randomisation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ljubomir Petricevic, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG. 2008 Oct;115(11):1369-74. doi: 10.1111/j.1471-0528.2008.01882.x.</citation>
    <PMID>18823487</PMID>
  </reference>
  <reference>
    <citation>Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004 Aug 14;329(7462):371. doi: 10.1136/bmj.38169.519653.EB. Epub 2004 Aug 4.</citation>
    <PMID>15294856</PMID>
  </reference>
  <results_reference>
    <citation>Farr A, Kiss H, Hagmann M, Machal S, Holzer I, Kueronya V, Husslein PW, Petricevic L. Role of Lactobacillus Species in the Intermediate Vaginal Flora in Early Pregnancy: A Retrospective Cohort Study. PLoS One. 2015 Dec 11;10(12):e0144181. doi: 10.1371/journal.pone.0144181. eCollection 2015.</citation>
    <PMID>26658473</PMID>
  </results_reference>
  <results_reference>
    <citation>Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Krondorfer I, Husslein P, Kneifel W, Kiss H. Characterisation of the vaginal Lactobacillus microbiota associated with preterm delivery. Sci Rep. 2014 May 30;4:5136. doi: 10.1038/srep05136.</citation>
    <PMID>24875844</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Associate Prof. Ljubomir Petricevic MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02979288
org study id: MUV 012017
nct id: NCT02979288
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
In the currently presented trial, investigators aim to evaluate the treatment of the
      intermediate vaginal microbiota during the first trimester of pregnancy with vaginal
      lactobacilli to restore the normal vaginal microbiota and therewith reduce the rate of PTD.
      All pregnant women between 10 + 0 (10 weeks plus 0 days) and 16 + 0 (16 weeks plus 0 days)
      gestational weeks in study group will be treated with vaginal Lactobacilli Capsules
      containing L. Casei rhamnosus LCR 35
Despite recent achievements in perinatal care, the prevention of preterm delivery (PTD)
      remains a major challenge in modern obstetrics. Healthy vaginal flora, dominated by
      Lactobacillus species (spp.), plays an important role in the protection against genital
      infections, which are considered a frequent cause of PTD. Imbalances of the vaginal flora
      caused by a reduction in the proportion of Lactobacillus spp. can lead to an overgrowth of
      mixed anaerobic bacteria, which can ultimately result in bacterial vaginosis (BV). Since the
      effect of treating pregnant women with an abnormal vaginal flora was introduced, BV has
      gained interest and is now a well-known risk factor for ascending infections and subsequent
      PTD. However, the overall risk reduction of PTD through antibiotic treatment of an abnormal
      flora was disproved by large and well-designed studies in a general obstetrical population.

      At present, little is known about the role of the intermediate vaginal flora, which can
      either be regarded as the transition from a healthy to an abnormal flora or as the transition
      from abnormal flora back to a healthy vaginal microbiota. The intermediate vaginal flora
      constitutes a highly heterogeneous group that may or may not include vaginal Lactobacillus
      spp. and that may or may not be characterised by the presence of anaerobic bacteria. In 2007,
      a meta-analysis reported that the presence of intermediate vaginal flora was not associated
      with PTD, late miscarriage, maternal or neonatal infection, or perinatal mortality. In
      contrast, an observational study by Hay et al.reported a high rate of late miscarriage (16-24
      gestational weeks) in women with intermediate vaginal flora at an examination before 16
      gestational weeks. Additionally, another study reported an association of PTD with partial
      BV, which is defined as streaks of BV flora in a smear that has areas of normal flora.

      Latest research reported that there is an association between the intermediate vaginal flora
      and PTD. In one of our previous studies, intermediate flora was identified on the examined
      screening smears of 529/8421 (6.3%) women. In this group, 349/529 (66%) women had a Nugent
      score of 4, 94/529 (17.8%) had a Nugent score of 5, and 86/529 (16.2%) had a Nugent score of
      6. In women with a Nugent score of 4, 232/349 (66.5%) women were assigned to the Lactobacilli
      group. The Non-Lactobacilli group consisted of 117/349 (33.5%) women with a Nugent score of 4
      due to the total absence of any bacterial colonisation, including Lactobacillus spp. The
      preterm delivery rate was significantly lower in the Lactobacilli than in the
      Non-Lactobacilli group On follow-up smears, bacterial vaginosis rates were 9% in the
      Lactobacilli and 7.8% in the Non-Lactobacilli group. Hence, according to this retrospective
      study, the absence of vaginal Lactobacillus species and any bacterial colonisation increases
      the risks of preterm delivery and low birth weight in women with intermediate vaginal flora
      in early pregnancy.

      In the currently presented trial, investigators aim to evaluate the treatment of the
      intermediate vaginal flora during the first trimester of pregnancy with vaginal lactobacilli
      to restore the normal vaginal microbiota and therewith reduce the rate of PTD.

      At investigators Department, pregnancy care includes a prenatal consultation, where women
      registered for a planned delivery at our department between 10 + 0 (10 weeks plus 0 days) and
      16 + 0 (16 weeks plus 0 days) gestational weeks. Women underwent routine screening for
      asymptomatic vaginal infections and characterization due to Nugent score. All women except
      those with a normal flora (Nugent score 0 to 3) will be asked to undergo a follow-up smear
      between 14 + 0 (14 weeks plus 0 days) and 22 + 0 (22 weeks plus 0 days) gestational weeks at
      our department. Vaginal smears will be obtained after vaginal fluid collection with sterile
      swabs from the lateral vaginal wall and posterior fornix vaginae. Both at first and control
      smear. All smears will be Gram-stained and microscopically analyzed by one of four biomedical
      laboratory assistants, specialized in gynecological cytopathology, at a laboratory that is
      certified according to DIN EN ISO 9001:2008. Nugent scores of 0 to 3 will be considered to
      indicate normal vaginal flora, 4 to 6 to indicate intermediate vaginal flora, and 7 to 10 to
      indicate BV.

      The present study follows a prospective randomized observer-blinded mono-centric design.
      After obtaining the results of vaginal swab According to the Nugent scoring system, two
      groups will be assigned: (i) pregnant women with an intermediate vaginal flora and a Nugent
      score of 4 with vaginal lactobacilli (Control Group), versus (ii) pregnant women with an
      intermediate vaginal flora and a Nugent score of 4 without vaginal lactobacilli (Study
      Group).

      Therapy will be assigned due to protocol. Each group will be divided in a study and control
      group. Patients of the study group will be treated with muco-adhesive slow release vaginal
      tablets containing 876,9 mg Lactobacillus casei rhamnosus (Lcr regenerans) in concentration
      of 107 CFU/ml (Groups A + C). The treatment duration will be 8 days with two tablets every
      4th day. Patients of the control group will not undergo any treatment (Groups B + D). A
      vaginal control smear will be obtained 4-6 weeks following the first study visit.

      The primary outcome parameter will be the recovery to the normal vaginal flora (Nugent score
      0 to 3). Secondary outcome parameters will include (i) the gestational age at delivery,
      recorded as term delivery at or after 37 + 0 gestational weeks, (ii) the rate of PTD, defined
      as spontaneous delivery at or before 36 + 6 gestational weeks, due to preterm premature
      rupture of the membranes and/or preterm labor, (iii) neonatal birthweight, defined as a the
      weight at the time of delivery, and (iv) the rate of live birth, defined as the delivery or
      PTD of an infant that had an Apgar score at 1 minute of > 0.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Single (Investigator)
measure: the recovery to the normal vaginal microbiota (Nugent score 0 to 3).
time frame: 4 Weeks
measure: the gestational age at delivery, recorded as term delivery at or after 37 + 0 gestational weeks
time frame: 9 Months
arm group label: A Nugent 4 + Lactobacilli
arm group type: Experimental
description: Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
arm group label: B Nugent 4 + Lactobacilli
arm group type: Active Comparator
description: Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
arm group label: C Nugent 4 NO Lactobacilli
arm group type: Experimental
description: Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
arm group label: D Nugent 4 NO Lactobacilli
arm group type: Active Comparator
description: Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
intervention type: Drug
intervention name: Lactobacillus casei rhamnosus (Lcr 35 regenerans)
description: Probiotic vaginal tablets vith active probiotic strains
arm group label: A Nugent 4 + Lactobacilli
arm group label: C Nugent 4 NO Lactobacilli
other name: Gynophilus
intervention type: Other
intervention name: NO Intervention
description: NO Intervention
arm group label: B Nugent 4 + Lactobacilli
arm group label: D Nugent 4 NO Lactobacilli
other name: NO Medication
criteria: 
gender: Female
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Ljubomir Petricevic, Prof
role: Study Chair
affiliation: Medical University Vienna
facility: 
country: Austria
citation: Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG. 2008 Oct;115(11):1369-74. doi: 10.1111/j.1471-0528.2008.01882.x.
PMID: 18823487
citation: Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004 Aug 14;329(7462):371. doi: 10.1136/bmj.38169.519653.EB. Epub 2004 Aug 4.
PMID: 15294856
citation: Farr A, Kiss H, Hagmann M, Machal S, Holzer I, Kueronya V, Husslein PW, Petricevic L. Role of Lactobacillus Species in the Intermediate Vaginal Flora in Early Pregnancy: A Retrospective Cohort Study. PLoS One. 2015 Dec 11;10(12):e0144181. doi: 10.1371/journal.pone.0144181. eCollection 2015.
PMID: 26658473
citation: Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Krondorfer I, Husslein P, Kneifel W, Kiss H. Characterisation of the vaginal Lactobacillus microbiota associated with preterm delivery. Sci Rep. 2014 May 30;4:5136. doi: 10.1038/srep05136.
PMID: 24875844
responsible party type: Principal Investigator
investigator affiliation: Medical University of Vienna
investigator full name: Associate Prof. Ljubomir Petricevic MD
investigator title: Associate Professor
sharing ipd: No